Skip to main content
. 2020 Jan 14;12(1):205. doi: 10.3390/cancers12010205

Table 1.

Ongoing clinical trials * involving mTOR in gynecological cancer.

Target Therapeutic Agent Carcinoma Trial Drug Design Reg. Nr.
mTORC1 everolimus EC Everolimus (RAD001) and Letrozole or Hormonal Therapy NCT02228681
Atypical hyperplasia or FIGO stage IA EC Levonorgestrel-Releasing Intrauterine System with or without Everolimus NCT02397083
OC, EC, CC Patients with alterations in PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss for maintenance therapy NCT02029001
everolimus
temsirolimus
Advanced OC Vemurafenib in Combination with Everolimus or Temsirolimus NCT01596140
sirolimus Stage II-IV OC The effects of TRICOM vaccine with sirolimus NCT01536054
mTORC1/2 Vistusertib
(AZD2014)
HR positive EC AZD2014 and anastrozole
vs. anastrozole alone
NCT02730923
Sapanisertib
MLN0128
EC and other solid tumors Single experimental arm: bevacizumab and MLN0128 NCT02142803
Sapanisertib
MLN0128
EC, OC Patients with mTOR mutation receive sapanisertib as a single experimental arm NCT02465060
AKT inhibitors miransertib
ARQ 092
OC, CC, EC ARQ 092 + paclitaxel or ARQ 092 + anastrozole NCT02476955
PI3K inhibition Copanlisib Hydrochloride CC, OC, EC Patients with a PI3K or a PTEN mutation receive copanlisib NCT02465060
GSK2636771 CC, OC, EC Patients with a PTEN mutation/expression/loss NCT02465060
Dual PI3K/mTOR inhibition Gedatolisib
PF-05212384
EC and other solid tumors Single experimental arm: palbociclib and gedatolisib NCT03065062
mTORC1/2 vs. AKT inhibition vistusertib
AZD2014 vs. capivasertib
AZD5363
Recurrent EC or OC (olaparib, vistusertib)
vs. (olaparib, capivasertib)
NCT02208375
Dual Akt/ERK inhibition ONC201 Recurrent or metastatic
EC
Single experimental arm: ONC201 treatment NCT03099499

* accurate data as of 3rd January 2020. Abbreviations: EC: endometrial cancer, OC: ovarian cancer, CC: cervical cancer, HR: hormone receptor; mTORC1: mammalian target of rapamycin complex 1, AKT: protein kinase B, PI3K: Phosphoinositide 3-kinase, mTOR: mammalian target of rapamycin.